Compare PTCT & NOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | NOV |
|---|---|---|
| Founded | 1998 | 1862 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.0B |
| IPO Year | 2006 | 1996 |
| Metric | PTCT | NOV |
|---|---|---|
| Price | $76.82 | $20.76 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 15 |
| Target Price | ★ $80.65 | $19.47 |
| AVG Volume (30 Days) | 1.5M | ★ 3.1M |
| Earning Date | 05-07-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | ★ 264.48 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $264,734,000.00 | ★ $8,744,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.70 | $3.81 |
| P/E Ratio | ★ N/A | $402.60 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $43.18 | $11.78 |
| 52 Week High | $90.87 | $21.55 |
| Indicator | PTCT | NOV |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 64.82 |
| Support Level | $74.45 | $17.92 |
| Resistance Level | $79.67 | $21.16 |
| Average True Range (ATR) | 3.27 | 0.51 |
| MACD | -1.01 | 0.25 |
| Stochastic Oscillator | 4.47 | 91.01 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
NOV (formerly National Oilwell Varco) designs, manufactures, and sells a wide range of equipment and components supplying the oil and gas industry, including rig equipment, downhole tools, drill pipe, and well casing. NOV's customers include major integrated oil companies, national oil companies, independent oil and gas companies, and drilling contractors. Its operations are organized into two reportable segments: energy products and services and energy equipment. NOV operates on a global scale, with international markets contributing nearly two-thirds of its annual revenue.